Special Products Limited has a board of four executive directors and three non-executive directors as well as the company secretary.
Dr. Graham March, PhD, MRPharmS – Non Executive Chairman
Dr Graham March is a pharmacist with more than 40 years’ experience gained at major pharmaceutical companies and in the NHS. He has particular expertise in the formulation of tablets, oral liquids and injections and quality control. Prior to founding Special Products, Dr March was a research pharmacist at Great Ormond Street Hospital for Children, where he developed a number of unlicensed medicines for rare inherited disorders. Earlier in his career, Dr March worked at AstraZeneca, with responsibility for the launch of several products in the UK, after which he was appointed to a number of roles at the Oxford Regional Health Authority.
Dr. Stephen Jones, PhD, MRPharmS – Group Chief Executive Officer
Dr Stephen Jones is a highly experienced pharmaceutical industry executive with a track record in branded medicines and consumer healthcare along with a successful history of new product development. Dr Jones has gained his experience working at major healthcare companies such as GlaxoSmithKline, Sterling Winthrop, Beecham Pharmaceuticals and Merck Sharp & Dohme. His most recent role was with the dermatology company Evocutis plc, where for the previous 6 years he held the post of Chief Executive Officer. In this role, he developed strategic initiatives, managed operational activities and negotiated commercial relationships.
Dr. Andrew Tittershill – Director Product Development, Supply & Support
Andrew is a Pharmacist and has a wealth of experience within the Pharmaceutical Industry in portfolio development and commercial activities associated with licensed and unlicensed medicines. He has worked for some large, international pharmaceutical companies in the past and more recently with mid-sized companies such as Martindale Pharma and Waymade Healthcare. Andrew is responsible for focusing on how best to maximise the opportunities within our current portfolio, and the identification, development and introduction of new products to help support the continued growth of Special Products Limited.
Bill Wild – Director Group Finance
Bill Wild is a highly experienced Chartered Accountant with a broad range of financial and commercial skills gained firstly at TT Electronics plc, the global electronics group, and then at Greenshields JCB, one of the world’s largest construction equipment dealers. Since joining Special Products in 2008, he has helped develop policies and procedures that ensure sound financial management and control of the company’s business. He was promoted to Head of Finance in October 2011 and then to Group Finance Director in September 2012, a role in which he focuses on providing financial oversight and strategic guidance to support the future growth of the company.
Chris Grimes – Director Commercial
Chris Grimes is a highly experienced commercial manager and has a wealth of experience within the pharmaceutical industry. Chris has gained vast experience managing and launching pharmaceutical products within global markets and delivering technology transfer projects on multiple product ranges. Previously Chris had worked for UCB Pharma Ltd within their Commercial Business, becoming Business Unit Manager of the Global Minijet Franchise. Chris now provides commercial oversight and strategic guidance to support the future growth of Special Products Limited.
Jason Saiban, LLB – Non-Executive Director
Jason Saiban is a partner at leading City law firm Charles Russell LLP. Jason specialises in commercial contracts and large scale projects and advises clients in a broad range of sectors from sports to charities. He has particular expertise in areas relevant to Special Products including healthcare, technology, distribution, licensing, procurement and outsourcing.
Theresa Wallis – Non-Executive Director
Theresa Wallis has an outstanding knowledge of the UK corporate landscape having worked for the London Stock Exchange for more than 12 years in roles including Chief Operating Officer of the AIM market. She currently advises a number of companies in non-executive and consultancy capacities. Theresa Wallis has a particular interest in the commercialisation of technology and worked for five years at Angle plc evaluating and advising early stage companies. She is currently non-executive chairman of LiDCO Group plc, a medical technology company, and is a non-executive director of the Quoted Companies Alliance.